Big changes at Novo Nordisk
Big changes at Novo Nordisk Danish giant Novo Nordisk is to stop small–molecule R&D activities. The company will instead focus on its protein–based pharmaceuticals. As a result, around 90 of Novo Nordisk’s 180 employees focused on this area are expected to be made redundant. Existing projects will be outlicensed.
15 June 2022
Startup Call Invites New Businesses to Turku